FR3015292A1 - COMPOSITION BASED ON OMEGA 6 AMIDE BOURRACHE - Google Patents
COMPOSITION BASED ON OMEGA 6 AMIDE BOURRACHE Download PDFInfo
- Publication number
- FR3015292A1 FR3015292A1 FR1303070A FR1303070A FR3015292A1 FR 3015292 A1 FR3015292 A1 FR 3015292A1 FR 1303070 A FR1303070 A FR 1303070A FR 1303070 A FR1303070 A FR 1303070A FR 3015292 A1 FR3015292 A1 FR 3015292A1
- Authority
- FR
- France
- Prior art keywords
- borage
- amide
- omega
- composition according
- salts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001408 amides Chemical class 0.000 title claims abstract description 47
- 241001072256 Boraginaceae Species 0.000 title claims abstract description 44
- 239000000203 mixture Substances 0.000 title claims abstract description 39
- 235000007689 Borago officinalis Nutrition 0.000 claims abstract description 43
- 208000003251 Pruritus Diseases 0.000 claims abstract description 18
- 206010061218 Inflammation Diseases 0.000 claims abstract description 10
- 230000000770 proinflammatory effect Effects 0.000 claims abstract description 10
- 239000002537 cosmetic Substances 0.000 claims abstract description 9
- 230000004054 inflammatory process Effects 0.000 claims abstract description 9
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- 230000028327 secretion Effects 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 12
- 150000002632 lipids Chemical class 0.000 claims description 11
- 239000011707 mineral Substances 0.000 claims description 9
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims description 7
- 229960002986 dinoprostone Drugs 0.000 claims description 7
- 230000005764 inhibitory process Effects 0.000 claims description 7
- 239000011777 magnesium Substances 0.000 claims description 7
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 claims description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 6
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 6
- 229910052749 magnesium Inorganic materials 0.000 claims description 6
- 239000011734 sodium Substances 0.000 claims description 6
- 229910052708 sodium Inorganic materials 0.000 claims description 6
- KGIJOOYOSFUGPC-CABOLEKPSA-N 5-HETE Natural products CCCCC\C=C/C\C=C/C\C=C/C=C/[C@H](O)CCCC(O)=O KGIJOOYOSFUGPC-CABOLEKPSA-N 0.000 claims description 5
- 229930184725 Lipoxin Natural products 0.000 claims description 5
- 150000002639 lipoxins Chemical class 0.000 claims description 5
- KGIJOOYOSFUGPC-MSFIICATSA-N 5-Hydroxyeicosatetraenoic acid Chemical compound CCCCCC=CCC=CCC=C\C=C\[C@@H](O)CCCC(O)=O KGIJOOYOSFUGPC-MSFIICATSA-N 0.000 claims description 4
- 239000011575 calcium Substances 0.000 claims description 4
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 claims description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 3
- PPCHNRUZQWLEMF-XBOCNYGYSA-N 18-HETE Chemical compound CCC(O)CC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O PPCHNRUZQWLEMF-XBOCNYGYSA-N 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- 239000006227 byproduct Substances 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims description 2
- 230000016571 aggressive behavior Effects 0.000 abstract description 4
- 230000015572 biosynthetic process Effects 0.000 abstract description 4
- 230000008238 biochemical pathway Effects 0.000 abstract description 2
- 238000001356 surgical procedure Methods 0.000 abstract 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 11
- 230000000638 stimulation Effects 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 235000021324 borage oil Nutrition 0.000 description 10
- 210000003491 skin Anatomy 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 8
- 230000003110 anti-inflammatory effect Effects 0.000 description 8
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 8
- 235000010755 mineral Nutrition 0.000 description 8
- -1 aminopropanediol amides Chemical class 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 239000010474 borage seed oil Substances 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 6
- 235000013619 trace mineral Nutrition 0.000 description 6
- 239000011573 trace mineral Substances 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- IXAQOQZEOGMIQS-SSQFXEBMSA-N lipoxin A4 Chemical compound CCCCC[C@H](O)\C=C\C=C/C=C/C=C/[C@@H](O)[C@@H](O)CCCC(O)=O IXAQOQZEOGMIQS-SSQFXEBMSA-N 0.000 description 5
- MXOAEAUPQDYUQM-QMMMGPOBSA-N (S)-chlorphenesin Chemical compound OC[C@H](O)COC1=CC=C(Cl)C=C1 MXOAEAUPQDYUQM-QMMMGPOBSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 4
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 4
- 241001135917 Vitellaria paradoxa Species 0.000 description 4
- 230000001139 anti-pruritic effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 229960000541 cetyl alcohol Drugs 0.000 description 4
- 229960003993 chlorphenesin Drugs 0.000 description 4
- 229940008099 dimethicone Drugs 0.000 description 4
- 239000004205 dimethyl polysiloxane Substances 0.000 description 4
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 4
- UXVRTOKOJOMENI-WLPVFMORSA-N lipoxin B4 Chemical compound CCCCC[C@H](O)[C@H](O)\C=C\C=C\C=C/C=C/[C@@H](O)CCCC(O)=O UXVRTOKOJOMENI-WLPVFMORSA-N 0.000 description 4
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 4
- 229940057910 shea butter Drugs 0.000 description 4
- 239000003643 water by type Substances 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
- FBNAWLJSQORPAX-UHFFFAOYSA-N 4-methyl-3-propan-2-ylphenol Chemical compound CC(C)C1=CC(O)=CC=C1C FBNAWLJSQORPAX-UHFFFAOYSA-N 0.000 description 3
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 3
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 3
- 229940075529 glyceryl stearate Drugs 0.000 description 3
- PMMXXYHTOMKOAZ-UHFFFAOYSA-N hexadecyl 7-methyloctanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCC(C)C PMMXXYHTOMKOAZ-UHFFFAOYSA-N 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- 229940048869 o-cymen-5-ol Drugs 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 229940068977 polysorbate 20 Drugs 0.000 description 3
- IKFAUGXNBOBQDM-XFMPMKITSA-N resolvin D2 Chemical compound CC\C=C/C[C@H](O)[C@H](O)\C=C\C=C\C=C/C=C/[C@@H](O)C\C=C/CCC(O)=O IKFAUGXNBOBQDM-XFMPMKITSA-N 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- 229920001285 xanthan gum Polymers 0.000 description 3
- 239000000230 xanthan gum Substances 0.000 description 3
- 229940082509 xanthan gum Drugs 0.000 description 3
- 235000010493 xanthan gum Nutrition 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- ZGCHLAJIRWDGFE-UHFFFAOYSA-N 1-aminopropane-1,1-diol Chemical class CCC(N)(O)O ZGCHLAJIRWDGFE-UHFFFAOYSA-N 0.000 description 2
- ILCOCZBHMDEIAI-UHFFFAOYSA-N 2-(2-octadecoxyethoxy)ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCO ILCOCZBHMDEIAI-UHFFFAOYSA-N 0.000 description 2
- ICIDSZQHPUZUHC-UHFFFAOYSA-N 2-octadecoxyethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCO ICIDSZQHPUZUHC-UHFFFAOYSA-N 0.000 description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 2
- KGKQNDQDVZQTAG-UHFFFAOYSA-N 8-methylnonyl 2,2-dimethylpropanoate Chemical compound CC(C)CCCCCCCOC(=O)C(C)(C)C KGKQNDQDVZQTAG-UHFFFAOYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 229920002367 Polyisobutene Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- FGUZFFWTBWJBIL-XWVZOOPGSA-N [(1r)-1-[(2s,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)O[C@H](CO)[C@H]1OC[C@H](O)[C@H]1O FGUZFFWTBWJBIL-XWVZOOPGSA-N 0.000 description 2
- FSEJJKIPRNUIFL-UHFFFAOYSA-N [2,2-bis(hydroxymethyl)-3-octadecanoyloxypropyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(CO)(CO)COC(=O)CCCCCCCCCCCCCCCCC FSEJJKIPRNUIFL-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 239000003908 antipruritic agent Substances 0.000 description 2
- 229940081733 cetearyl alcohol Drugs 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000003589 local anesthetic agent Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 231100000956 nontoxicity Toxicity 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 229940100460 peg-100 stearate Drugs 0.000 description 2
- 229960005323 phenoxyethanol Drugs 0.000 description 2
- BTSZTGGZJQFALU-UHFFFAOYSA-N piroctone olamine Chemical compound NCCO.CC(C)(C)CC(C)CC1=CC(C)=CC(=O)N1O BTSZTGGZJQFALU-UHFFFAOYSA-N 0.000 description 2
- 229940081510 piroctone olamine Drugs 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000006748 scratching Methods 0.000 description 2
- 230000002393 scratching effect Effects 0.000 description 2
- 229940057429 sorbitan isostearate Drugs 0.000 description 2
- 229940098760 steareth-2 Drugs 0.000 description 2
- 229940100458 steareth-21 Drugs 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 2
- DWANEFRJKWXRSG-UHFFFAOYSA-N 1,2-tetradecanediol Chemical compound CCCCCCCCCCCCC(O)CO DWANEFRJKWXRSG-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- LRWYBGFSVUBWMO-UAAZXLHOSA-N 18(R)-HEPE Chemical compound CC[C@@H](O)\C=C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O LRWYBGFSVUBWMO-UAAZXLHOSA-N 0.000 description 1
- 235000005637 Brassica campestris Nutrition 0.000 description 1
- 241001301148 Brassica rapa subsp. oleifera Species 0.000 description 1
- 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 description 1
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 description 1
- 102000009135 CB2 Cannabinoid Receptor Human genes 0.000 description 1
- 108010073376 CB2 Cannabinoid Receptor Proteins 0.000 description 1
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 1
- 108050007331 Cannabinoid receptor Proteins 0.000 description 1
- AERBNCYCJBRYDG-UHFFFAOYSA-N D-ribo-phytosphingosine Natural products CCCCCCCCCCCCCCC(O)C(O)C(N)CO AERBNCYCJBRYDG-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 description 1
- 229920001908 Hydrogenated starch hydrolysate Polymers 0.000 description 1
- WYQVAPGDARQUBT-FGWHUCSPSA-N Madecassol Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(CC[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O WYQVAPGDARQUBT-FGWHUCSPSA-N 0.000 description 1
- PVLJETXTTWAYEW-UHFFFAOYSA-N Mizolastine Chemical compound N=1C=CC(=O)NC=1N(C)C(CC1)CCN1C1=NC2=CC=CC=C2N1CC1=CC=C(F)C=C1 PVLJETXTTWAYEW-UHFFFAOYSA-N 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 235000011034 Rubus glaucus Nutrition 0.000 description 1
- 244000235659 Rubus idaeus Species 0.000 description 1
- 235000009122 Rubus idaeus Nutrition 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 108010025083 TRPV1 receptor Proteins 0.000 description 1
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 description 1
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000005250 alkyl acrylate group Chemical group 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- WYQVAPGDARQUBT-XCWYDTOWSA-N asiaticoside Natural products O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@@]4(C)[C@H]([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2 WYQVAPGDARQUBT-XCWYDTOWSA-N 0.000 description 1
- 229940022757 asiaticoside Drugs 0.000 description 1
- QCYLIQBVLZBPNK-UHFFFAOYSA-N asiaticoside A Natural products O1C(C(=O)C(C)C)=CC(C)C(C2(C(OC(C)=O)CC34C5)C)C1CC2(C)C3CCC(C1(C)C)C45CCC1OC1OCC(O)C(O)C1O QCYLIQBVLZBPNK-UHFFFAOYSA-N 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 239000003554 cannabinoid 1 receptor agonist Substances 0.000 description 1
- 239000003556 cannabinoid 2 receptor agonist Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229940080421 coco glucoside Drugs 0.000 description 1
- RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 229960003592 fexofenadine Drugs 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000008269 hand cream Substances 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- OQJBSDFFQWMKBQ-UHFFFAOYSA-N isothipendyl Chemical group C1=CN=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 OQJBSDFFQWMKBQ-UHFFFAOYSA-N 0.000 description 1
- 229960003517 isothipendyl Drugs 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- OAIQHKWDTQYGOK-UHFFFAOYSA-L magnesium;2-[2-(2-dodecoxyethoxy)ethoxy]ethyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOCCOCCOCCOS([O-])(=O)=O.CCCCCCCCCCCCOCCOCCOCCOS([O-])(=O)=O OAIQHKWDTQYGOK-UHFFFAOYSA-L 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229960001144 mizolastine Drugs 0.000 description 1
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 1
- 230000003040 nociceptive effect Effects 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940086539 peg-7 glyceryl cocoate Drugs 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- AERBNCYCJBRYDG-KSZLIROESA-N phytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO AERBNCYCJBRYDG-KSZLIROESA-N 0.000 description 1
- 229940033329 phytosphingosine Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000037457 pro-inflammatory mechanism Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940079781 sodium cocoyl glutamate Drugs 0.000 description 1
- 229940057950 sodium laureth sulfate Drugs 0.000 description 1
- SXHLENDCVBIJFO-UHFFFAOYSA-M sodium;2-[2-(2-dodecoxyethoxy)ethoxy]ethyl sulfate Chemical compound [Na+].CCCCCCCCCCCCOCCOCCOCCOS([O-])(=O)=O SXHLENDCVBIJFO-UHFFFAOYSA-M 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
- A61K35/08—Mineral waters; Sea water
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Birds (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cosmetics (AREA)
Abstract
L'invention concerne une composition cosmétique et/ou dermatologique destinée au traitement des peaux prurigineuses et enflammées à travers diverses voies biochimiques. Elle comprend à titre de principe actif l'oméga 6 amide bourrache qui permet de stimuler la formation de molécules naturelles participant à la résolution de l'inflammation cutanée et d'inhiber la production de certaines molécules pro-inflammatoires sécrétées par l'organisme lors d'une agression cutanée.The invention relates to a cosmetic and / or dermatological composition for the treatment of itchy skin and inflamed through various biochemical pathways. It includes as active ingredient omega 6 borage amide which stimulates the formation of natural molecules involved in the resolution of cutaneous inflammation and inhibit the production of certain pro-inflammatory molecules secreted by the body during surgery. a cutaneous aggression.
Description
Le secteur technique de la présente invention est celui des compositions destinées à traiter les peaux prurigineuses et/ou enflammées. Le prurit est un signe fonctionnel et se définit comme 5 « une sensation qui provoque le besoin de se gratter ». Il peut être localisé ou généralisé. Le prurit devient pathologique lorsqu'il induit des lésions de grattage. Il existe de nombreux stimuli au prurit, des stimuli externes (physiques ou chimiques) mais aussi très souvent des stimuli 10 endogènes (histamine, protéases, prostaglandines, neuropeptides). Tous les stimuli du prurit ne sont pas connus. Au niveau de la peau, le prurit est enregistré par les terminaisons nociceptives non myélinisées C (terminaisons libres). Typiquement, le prurit entraîne « le besoin de se 15 gratter » puis une irritation douloureuse engendrée par le grattage et l'augmentation des phénomènes inflammatoires subséquents. On peut alors tomber dans le prurit chronique. La plupart des compositions dermatologiques antiprurigineuses ou anti-inflammatoires actuelles 20 comprennent des molécules antihistaminiques (fexofénadine, mizolastine, isothipendyl) à ingérer ou à appliquer localement, mais également des anesthésiques locaux, des antiseptiques ou même des corticoïdes (hydrocortisone). Néanmoins, certains de ces composés peuvent s'avérer 25 agressifs pour la peau (notamment les corticoïdes) et/ou présenter des effets secondaires indésirables. Une des voies récemment empruntées pour traiter le prurit concerne une action sur les récepteurs aux cannabinoïdes à l'aide de molécules spécifiques comprises dans des 30 compositions pharmaceutiques (EP2130820). Dans ce dernier document, il est divulgué que des composés agonistes des récepteurs aux cannabinoïdes CB1 et CB2 ont un effet antiprurigineux dans des compositions administrées par voie orale, et que les composés ayant une activité antagonistes de 35 ces récepteurs bloquent efficacement l'effet antiprurigineux des composés agonistes. Cependant, la plupart des composés antiprurigineux ou efficace contre inflammation cutanée sont intégrés dans des compositions souvent complexes, notamment celles comprenant un antiseptique, un anesthésiant local, plusieurs antiprurigineux, un corticoïde, etc. Ces compositions présentent fréquemment une certaine toxicité pour la peau humaine et/ou des effets secondaires indésirables. On recherche donc toujours activement des composés significativement efficaces contre les phénomènes inflammatoires cutanés et bien toléré par l'organisme. La présente invention propose de répondre à ce besoin 10 avec des compositions cosmétiques et/ou dermatologiques comprenant à titre de principe actif l'oméga 6 amide bourrache. Les auteurs de la présente invention ont découvert de manière totalement fortuite et avec surprise qu'une 15 composition comprenant à titre de principe actif l'oméga 6 amide bourrache permettait de participer à la résolution (l'arrêt) de la réaction inflammatoire cutanée en favorisant la sécrétion de molécules anti-inflammatoires et en inhibant la sécrétion de molécules pro-inflammatoires, et ce sans 20 aucun effet secondaire indésirable. L'invention a donc pour objet une composition cosmétique et/ou dermatologique, caractérisée en ce qu'elle comprend à titre de principe actif l'oméga 6 amide bourrache selon une 25 proportion massique supérieure ou égale à 0,001%, les autres ingrédients étant constitués par des produits admissibles dans les domaines cosmétique et/ou dermatologique, pour son utilisation dans la stimulation de la sécrétion par l'organisme de molécules participant à la résolution de 30 l'inflammation cutanée telles que les lipoxines, résolvines et marésines, et l'inhibition de la sécrétion de molécules pro-inflammatoires telles que les médiateurs lipidiques PGE2, 5-HETE, 18-HETE et LTB4. Selon une autre caractéristique de l'invention, la 35 composition est caractérisée en ce que l'oméga 6 amide bourrache se trouve dans une proportion massique comprise entre 0,001% et 10%.The technical field of the present invention is that of compositions intended for treating itchy and / or inflamed skin. Pruritus is a functional sign and is defined as "a sensation that causes the need to scratch". It can be localized or generalized. Pruritus becomes pathological when it induces scratching lesions. There are many pruritus stimuli, external stimuli (physical or chemical) but also very often endogenous stimuli (histamine, proteases, prostaglandins, neuropeptides). All pruritus stimuli are not known. In the skin, pruritus is recorded by non-myelinated nociceptive C endings (free endings). Typically, itching causes "the need to scratch" and then a painful irritation caused by scratching and subsequent inflammatory phenomena. We can then fall into chronic pruritus. Most current antipruriginous or anti-inflammatory dermatological compositions include antihistaminic molecules (fexofenadine, mizolastine, isothipendyl) for ingesting or topical application, but also local anesthetics, antiseptics or even corticosteroids (hydrocortisone). Nevertheless, some of these compounds may be aggressive to the skin (especially corticosteroids) and / or have undesirable side effects. One of the recently used routes for treating pruritus involves action on cannabinoid receptors using specific molecules included in pharmaceutical compositions (EP2130820). In this latter document, it is disclosed that CB1 and CB2 cannabinoid receptor agonist compounds have antipruritic effect in orally administered compositions, and that compounds having antagonist activity of these receptors effectively block the antipruritic effect of the agonist compounds. However, most of the antipruritic or effective anti-inflammation compounds are incorporated in often complex compositions, including those comprising an antiseptic, a local anesthetic, several antipruriginous, a corticoid, etc. These compositions frequently exhibit some toxicity to human skin and / or undesirable side effects. Therefore, we are still actively seeking compounds that are significantly effective against cutaneous inflammatory phenomena and well tolerated by the body. The present invention proposes to meet this need with cosmetic and / or dermatological compositions comprising, as active principle, omega 6 borage amide. The authors of the present invention have discovered in a totally fortuitous and surprising manner that a composition comprising, as an active principle, omega 6 borage amide makes it possible to participate in the resolution (arrest) of the cutaneous inflammatory reaction by promoting the secretion of anti-inflammatory molecules and by inhibiting the secretion of pro-inflammatory molecules, without any undesirable side effects. The subject of the invention is therefore a cosmetic and / or dermatological composition, characterized in that it comprises, as active ingredient, omega 6 borage amide in a mass proportion of greater than or equal to 0.001%, the other ingredients consisting of by products which are eligible in the cosmetic and / or dermatological fields, for its use in stimulating the secretion by the body of molecules involved in the resolution of cutaneous inflammation such as lipoxins, resolvinins and marines, and inhibition of the secretion of pro-inflammatory molecules such as lipid mediators PGE2, 5-HETE, 18-HETE and LTB4. According to another characteristic of the invention, the composition is characterized in that the omega 6 borage amide is in a mass proportion of between 0.001% and 10%.
Selon encore une autre caractéristique de l'invention, la composition est caractérisée en ce qu'elle comprend 0,002% en masse d'oméga 6 amide bourrache. Selon une autre caractéristique de l'invention, la 5 composition est caractérisée en ce qu'elle comprend 0,01% en masse d'oméga 6 amide bourrache. Selon encore une autre caractéristique de l'invention, la composition est caractérisée en ce qu'elle comprend 0,1% en masse d'oméga 6 amide bourrache. 10 Selon une autre caractéristique de l'invention, la composition est caractérisée en ce qu'elle comprend 1% en masse d'oméga 6 amide bourrache. Selon encore une autre caractéristique de l'invention, la composition est caractérisée en ce qu'elle comprend 5% en 15 masse d'oméga 6 amide bourrache. Selon une autre caractéristique de l'invention, la composition est caractérisée en ce qu'elle comprend en outre en tant que principe actif une eau minérale comprenant - entre 40 mg/L et 600 mg/L de calcium, et/ou de sels 20 et/ou de dérivés de celui-ci, - entre 12,5 mg/L et 125 mg/L de magnésium, et/ou de sels et/ou de dérivés de celui-ci, - entre 0,455 mg/L et 45,5 mg/L de potassium, et/ou de sels et/ou de dérivés de celui-ci, 25 - entre 23,6 mg/L et 2360 mg/L de sodium, et/ou de sels et/ou de dérivés de celui-ci, selon une proportion massique comprise entre 1% et 99%. Selon encore une autre caractéristique de l'invention, la composition est caractérisée en ce qu'elle comprend l'Eau 30 Thermale d'Uriage. Selon une autre caractéristique de l'invention, la composition est utilisée pour traiter l'inflammation cutanée. Selon encore une autre caractéristique de l'invention, la composition est utilisée pour traiter le prurit. 35 Un premier avantage de l'invention est une action significative contre les réactions inflammatoires cutanées par une voie biochimique totalement naturelle.According to yet another characteristic of the invention, the composition is characterized in that it comprises 0.002% by weight of omega 6 borage amide. According to another characteristic of the invention, the composition is characterized in that it comprises 0.01% by mass of omega 6 borage amide. According to yet another characteristic of the invention, the composition is characterized in that it comprises 0.1% by weight of omega 6 borage amide. According to another characteristic of the invention, the composition is characterized in that it comprises 1% by weight of omega 6 borage amide. According to yet another characteristic of the invention, the composition is characterized in that it comprises 5% by mass of omega 6 borage amide. According to another characteristic of the invention, the composition is characterized in that it further comprises, as active principle, a mineral water comprising - between 40 mg / l and 600 mg / l of calcium, and / or salts and / or derivatives thereof, - between 12.5 mg / L and 125 mg / L magnesium, and / or salts and / or derivatives thereof, - between 0.455 mg / L and 45, 5 mg / L of potassium, and / or of salts and / or derivatives thereof, between 23.6 mg / L and 2360 mg / L of sodium, and / or of salts and / or derivatives of it, in a mass proportion of between 1% and 99%. According to yet another characteristic of the invention, the composition is characterized in that it comprises Uriage Thermal Water. According to another characteristic of the invention, the composition is used to treat cutaneous inflammation. According to yet another characteristic of the invention, the composition is used to treat pruritus. A first advantage of the invention is a significant action against cutaneous inflammatory reactions by a completely natural biochemical pathway.
Un deuxième avantage de l'invention est la prévention des inflammations cutanées par la stimulation de molécules anti-inflammatoires même en l'absence d'agression cutanée. Un troisième avantage de l'invention est de prévenir 5 l'apparition du prurit ou bien encore de participer à sa résolution. Un dernier avantage de l'invention est sa totale innocuité pour l'organisme humain. 10 Par oméga 6 amide bourrache, en entend les amides particuliers d'huile de bourrache désignés par le nom INCI «Borage seed oil aminopropanediol amides», d'origine végétale et obtenus par biotechnologie enzymatique. L'huile de bourrache est de plus en plus utilisée en 15 cosmétologie, notamment en raison de sa forte teneur en oméga 6. Néanmoins, très peu d'inventions encore impliquent des amides d'huile de bourrache. Comme l'huile de bourrache, l'oméga 6 amide bourrache ne présente aucune toxicité pour la peau. 20 Les auteurs de la présente invention ont découvert avec surprise que l'application locale de l'oméga 6 amide bourrache permettait de participer à la résolution (l'arrêt) de la réaction inflammatoire cutanée en favorisant la formation de lipoxines, résolvines et marésines, et en 25 inhibant la formation de molécules pro-inflammatoires sécrétées en cas d'agression cutanée. Les molécules anti ou pro-inflammatoires respectivement stimulées ou inhibées grâce à la présente invention sont des médiateurs lipidiques naturellement sécrétés par l'organisme. 30 Ainsi, une composition cosmétique et/ou dermatologique comprenant l'oméga 6 amide bourrache permet le traitement des peaux prurigineuses et/ou enflammées à travers un mécanisme biochimique totalement naturel. Il est évident que son application locale se fait au sein 35 de compositions cosmétiques et/ou dermatologiques dont les autres ingrédients sont des composés acceptables dans ces domaines.A second advantage of the invention is the prevention of skin inflammations by the stimulation of anti-inflammatory molecules even in the absence of cutaneous aggression. A third advantage of the invention is to prevent the appearance of pruritus or to participate in its resolution. A final advantage of the invention is its total safety for the human body. By omega 6 borage amide means the particular amides of borage oil referred to by the INCI name Borage seed oil aminopropanediol amides, of plant origin and obtained by enzymatic biotechnology. Borage oil is increasingly used in cosmetology, in particular because of its high omega-6 content. Nevertheless, very few inventions still involve borage oil amides. Like borage oil, omega 6 borage amide has no toxicity to the skin. The authors of the present invention have surprisingly discovered that the local application of borage omega 6 amide makes it possible to participate in the resolution (arrest) of the cutaneous inflammatory reaction by promoting the formation of lipoxins, resolvers and marines, and by inhibiting the formation of secreted pro-inflammatory molecules in case of skin aggression. The anti or pro-inflammatory molecules respectively stimulated or inhibited by the present invention are lipid mediators naturally secreted by the body. Thus, a cosmetic and / or dermatological composition comprising omega 6 borage amide allows the treatment of itchy and / or inflamed skin through a completely natural biochemical mechanism. It is obvious that its local application is within cosmetic and / or dermatological compositions whose other ingredients are acceptable compounds in these fields.
Il est tout à fait possible de combiner l'oméga 6 amide bourrache compris dans la composition selon l'invention avec d'autres principes actifs efficaces dans le traitement de la peau enflammée, irritée et/ou prurigineuse. Par exemple, on peut combiner l'oméga 6 amide bourrache avec certaines eaux minérales riches en oligo-éléments et sels minéraux, telles que l'Eau Thermale d'Uriage (dont le nom INCI UE est « Uriage Thermal Spring Water ») ou l'Eau Thermale d'Avène. Par eaux minérales riches en oligo-éléments et sels minéraux, on entend des eaux minérales ayant des proportions significativement élevées et définies de calcium, magnésium, magnésium et sodium, et/ou des sels et/ des dérivés de ceux-ci, et un ratio massique Ca/Mg compris entre 1 et 10. Selon sa teneur en sels minéraux, l'eau minérale, à titre de principe actif en combinaison avec l'oméga 6 amide bourrache, peut être présente dans une composition cosmétique et/ou dermatologique antiprurigineuse et/ou anti-inflammatoire selon une proportion allant de 1 à 99%. Une telle eau minérale permet de traiter le prurit et les affections afférentes par des voies biochimiques différentes de celle de l'oméga 6 amide bourrache selon l'invention, c'est-à-dire en diminuant de la libération de TSLP et/ou en régulant le récepteur TRPV1 et les récepteurs aux cannabinoïdes CB1 et CB2. Ainsi, il est possible de combattre le prurit et/ou de traiter les peaux enflammées à travers une vaste gamme de processus biochimiques simultanés. Enfin, comme l'oméga 6 amide bourrache selon l'invention, les eaux minérales riches en oligo-éléments et sels minéraux ne présente aucune toxicité pour l'homme.It is quite possible to combine omega 6 borage amide included in the composition according to the invention with other active ingredients effective in the treatment of inflamed skin, irritated and / or itchy. For example, omega 6 borage amide may be combined with certain mineral waters rich in trace elements and mineral salts, such as Uriage Thermal Water (whose INCI EU name is "Uriage Thermal Spring Water") or Avene Thermal Water. By mineral waters rich in trace elements and mineral salts is meant mineral waters having significantly high and defined proportions of calcium, magnesium, magnesium and sodium, and / or salts and / or derivatives thereof, and a ratio of mass Ca / Mg between 1 and 10. According to its mineral salts content, mineral water, as active ingredient in combination with omega 6 borage amide, may be present in an antipruritic cosmetic and / or dermatological composition and / or anti-inflammatory in a proportion ranging from 1 to 99%. Such mineral water makes it possible to treat the pruritus and the afferent affections by biochemical routes different from that of the borage omega 6 amide according to the invention, that is to say by decreasing the release of TSLP and / or by regulating TRPV1 receptor and CB1 and CB2 cannabinoid receptors. Thus, it is possible to combat pruritus and / or treat inflamed skin through a wide range of simultaneous biochemical processes. Finally, as omega 6 borage amide according to the invention, the mineral waters rich in trace elements and mineral salts has no toxicity to humans.
Les auteurs de la présente invention ont évalué l'effet de l'oméga 6 amide bourrache sur la synthèse de molécules participant à la résolution de l'inflammation et de molécules pro-inflammatoires.The authors of the present invention evaluated the effect of omega 6 borage amide on the synthesis of molecules involved in the resolution of inflammation and pro-inflammatory molecules.
Protocole d'étude: Des kératinocytes en culture primaire (NHEK) sont préparés. Après une semaine, les NHEK sont déposés dans des inserts, puis l'oméga 6 amide bourrache aux concentrations massiques 0,0005% et 0,005% est ajouté sur les NHEK. Après un jour de stimulation avec l'actif, on ajoute la stimulation inflammatoire (PMA/A23187) et/ou les AGPI (acides 5 gras polyinsaturés) DHA/EPA selon un plan de plaque prédéfini. Les AGPI (DHA/EPA) constituent le substrat lipidique qui sert à former les médiateurs lipidiques. Parmi les médiateurs anti-inflammatoire on trouve en particulier des lipoxines (dont LXA4 et LXB4), des résolvines (dont RvD2) 10 et des marésines (dont 7-(R)MarRl). Parmi les médiateurs pro- inflammatoires on trouve en particulier LTB4, 5-HETE, PGE2 et 18-HEPE. lh après les surnageants de culture ont été prélevés pour analyse des médiateurs lipidiques. Tableau des résultats Valeur d'induction (en %) par rapport au contrôle (CTRL) de chaque condition Milieu testé / CTRL sans oméga 6 amide bourrache Oméga 6 amide bourrache Médiateurs lipidiques anti- inflammatoires Médiateurs lipidiques pro-inflammatoires (% massique) LXA4 LXB4 RvD2 7-(R)Mar R1 PGE2 5- HETE 18- HEPE LTB4 Effet propre (oméga 6 amide bourrache seul) 0,005 10 183 1 202 26 005 7 678 -56 # 0 0 0,0005 0 e 0 0 5 # 0 0 AGPI (substrat lipidique) 0,005 2 191 1 636 33 708 8 183 -63 -97 -19 0 0,0005 # e 0 0 -14 44 -15 # PMA/A23 (stimulation inflammatoire) 0,005 9 088 4 389 26 190 9 377 -65 -87 # -99 0,0005 0 e 0 0 172 4 -17 AGPI+PMA/A23 0,005 11 701 3 397 24 251 6 067 -80 -96 -42 -98 0,0005 0 -70 0 0 58 -29 0 -16 #Contrôle et test en dessous de la limite de quantification donc induction non significative.Study protocol: Primary culture keratinocytes (NHEK) are prepared. After one week, the NHEKs are deposited in inserts, then the omega 6 borage amide at 0.0005% mass concentrations and 0.005% is added to the NHEKs. After one day of stimulation with the active ingredient, the inflammatory stimulation (PMA / A23187) and / or PUFA (polyunsaturated fatty acids) DHA / EPA are added according to a predefined plate plan. PUFA (DHA / EPA) is the lipid substrate used to form lipid mediators. Among the anti-inflammatory mediators, there are in particular lipoxins (including LXA4 and LXB4), resolvins (including RvD2), and marines (including 7- (R) MarR1). Among the inflammatory mediators, there are in particular LTB4, 5-HETE, PGE2 and 18-HEPE. 1h after culture supernatants were taken for analysis of lipid mediators. Table of results Induction value (in%) relative to the control (CTRL) of each condition Test medium / CTRL without omega 6 amide borage Omega 6 amide Borage Anti-inflammatory lipid mediators Proinflammatory lipid mediators (% by mass) LXA4 LXB4 RvD2 7- (R) Mar R1 PGE2 5- HETE 18- HEPE LTB4 Clean effect (omega 6 amide borage alone) 0.005 10 183 1 202 26 005 7 678 -56 # 0 0 0.0005 0 e 0 0 5 # 0 0 PUFA (lipid substrate) 0.005 2 191 1 636 33 708 8 183 -63 -97 -19 0 0.0005 # e 0 0 -14 44 -15 # PMA / A23 (inflammatory stimulation) 0.005 9 088 4 389 26 190 9 377 -65 -87 # -99 0.0005 0 e 0 0 172 4 -17 PUFA + PMA / A23 0.005 11 701 3 397 24 251 6 067 -80 -96 -42 -98 0.0005 0 -70 0 0 58 - 29 0 -16 # Control and test below the limit of quantification so inductive induction.
Un pourcentage d'induction positif correspond à une stimulation de la sécrétion du médiateur par rapport au contrôle (CTRL) effectué dans les mêmes conditions sans oméga 6 amide bourrache. Ainsi par exemple, l'effet propre de l'oméga 6 amide bourrache à 0,005% pour le médiateur LXA4 correspond à une augmentation de 10 183% de la sécrétion de LXA4 par rapport au contrôle sans oméga 6 amide bourrache. De même, l'effet de l'oméga 6 amide bourrache avec AGPI à 0,0005% pour le médiateur lipidique PGE2 correspond à une augmentation de 5% de la sécrétion de PGE2 par rapport au contrôle avec AGPI mais sans oméga 6 amide bourrache. Un pourcentage d'induction négatif correspond à une inhibition de la sécrétion du médiateur (il ne peut donc être inférieur à -100).A percentage of positive induction corresponds to a stimulation of the secretion of the mediator relative to the control (CTRL) carried out under the same conditions without omega 6 borage amide. For example, the effect of the omega 6 borage amide at 0.005% for the LXA4 mediator corresponds to a 183% increase in the secretion of LXA4 compared to the control without omega 6 borage amide. Similarly, the effect of omega 6 borage amide with 0.0005% PUFA for the lipid mediator PGE2 corresponds to a 5% increase in the secretion of PGE2 compared to control with PUFA but without omega 6 borage amide. A percentage of negative induction corresponds to an inhibition of the secretion of the mediator (it can not be less than -100).
Le pourcentage d'induction est interprété de la façon suivante : - supérieur à 200 : forte stimulation ; - entre 100 et 200 : stimulation nette ; - entre 50 et 100 : stimulation modérée ; - entre -35 et 50 : neutre (pas d'influence significative sur la sécrétion) ; - entre -35 et -50 : inhibition modérée ; - entre -50 et -70 : inhibition nette ; - inférieur à -70 : inhibition forte.The percentage of induction is interpreted as follows: greater than 200: strong stimulation; between 100 and 200: net stimulation; - between 50 and 100: moderate stimulation; - between -35 and 50: neutral (no significant influence on secretion); - between -35 and -50: moderate inhibition; - between -50 and -70: net inhibition; - less than -70: strong inhibition.
La sécrétion des médiateurs anti-inflammatoires LXA4, LXB4, RvD2 et 7-(R)MarRl est fortement stimulée à 0,005% massique d'oméga 6 amide bourrache, et ce quel que soit le milieu (seul, avec AGPI, avec PMA/A23 ou avec AGPI et PMA/A23). À l'inverse, la sécrétion de plusieurs médiateurs pro-inflammatoires est significativement inhibée, en particulier en condition AGPI+PMA/A23. Ces résultats sont d'autant plus surprenants qu'ils n'apparaissent absolument pas à 0,0005% massique d'oméga 6 amide bourrache. En effet dans cette proportion, l'oméga 6 amide bourrache n'a qu'un effet neutre ou bien favorise légèrement les mécanismes pro-inflammatoires, avec une inhibition nette de LXB4 dans le cas AGPI+PMA/A23, une stimulation nette de PGE2 dans le cas AGPI+PMA/A23, et une stimulation modérée de 5-HETE avec le cas AGPI.The secretion of the anti-inflammatory mediators LXA4, LXB4, RvD2 and 7- (R) MarR1 is strongly stimulated to 0.005% by mass of omega 6 borage amide, irrespective of the medium (alone, with PUFA, with PMA / A23 or with PUFA and PMA / A23). On the other hand, the secretion of several pro-inflammatory mediators is significantly inhibited, in particular in the AGPI + PMA / A23 condition. These results are all the more surprising as they do not appear at 0.0005% by weight of omega 6 borage amide. Indeed, in this proportion, omega 6 borage amide has only a neutral effect or slightly favors pro-inflammatory mechanisms, with a clear inhibition of LXB4 in the case of PUFA + PMA / A23, a net stimulation of PGE2. in the case of AGPI + PMA / A23, and moderate stimulation of 5-HETE with the PUFA case.
Conclusion On constate qu'à la concentration 0,005%, l'oméga 6 amide bourrache stimule significativement la sécrétion des médiateurs lipidiques résolvines, lipoxines et marésines 5 (respectivement appelés de façon générique Rv, LX et Mar), molécules naturelles particulièrement impliquées dans la résolution de l'inflammation cutanée. De plus, l'oméga 6 amide bourrache inhibe significativement la sécrétion de molécules pro-inflammatoires naturellement produites par 10 l'organisme lors d'une agression cutanée (stimulation inflammatoire). Exemples de compositions comprenant l'oméga 6 amide bourrache amides (nom INCI UE : « Borage seed oil 15 aminopropanediol amides ») selon l'invention : Exemple 1 : Lait anti-prurit - Emulsion H/E Nom INCI UE % (masse) Aqua qsp Uriage Thermal Spring Water 35 Borage seed oil aminopropanediol amides 0,002 Butyrospermum parkll (shea butter) 5 Cetearyl isononanoate 5 Isodecyl neopentanoate 4 Butylene glycol 3 Glycerin 3 Hydrogenated polydecene 2,5 Dimethicone 2 Squalane 2 Steareth-2 2 Steareth-21 2 Cetyl alcohol 1 Pentaerythrityl distearate 1 Polyacrylate-13 0,6 Brassica campestris sterols 0,5 Chlorphenesin 0,3 Piroctone olamine 0,3 Polyisobutene 0,27 Sodium dextran sulfate 0,2 Citric acid 0,1 o-cymen-5-ol 0,1 Tocopheryl acetate 0,1 Xanthan gum 0,1 Raspberry seed oil/palm oil aminopropanediol esters 0,05 Polysorbate 20 0,045 Sorbitan isostearate 0,04 Asiaticoside 0,02 Phytosphingosine 0,02 Exemple 2 : Huile nettoyante Nom INCI UE % (masse) Aqua qsp Uriage Thermal Spring Water 5 Borage seed oil aminopropanediol amides 0,01 Glycerin 19 Hydrogenated starch hydrolysate 15,4 PEG-7 glyceryl cocoate 2 Sodium cocoyl glutamate 1,8 Sodium laureth sulfate 1,8 Sodium laureth-8 sulfate 1,62 Ceteareth-60 myristyl glycol 1 Polysorbate 20 0,97 Coco-glucoside 0,66 Glyceryl oleate 0,66 Sodium chloride 0,646 Citric acid 0,54 Magnesium laureth sulfate 0,45 Sodium oleth sulfate 0,45 Polyquaternum-10 0,364 Magnesium laureth-8 sulfate 0,36 PEG-75 shea butter glycerides 0,25 Magnesium oleth sulfate 0,09 Sodium acetate 0,006 Exemple 3 : Crème mains Nom INCI UE % (masse) Aqua qsp Uriage Thermal Spring Water 15 Borage seed oil aminopropanediol amides 0,1 Glycerin 3 Phenoxyethanol 0,5 Chlorphenesin 0,2 Acrylates/C10-30 alkyl acrylate crosspolymer 0,17 Glyceryl stearate PEG-100 stearate 3 Cetyl alcohol 2 Cetearyl isononoate 4 Squalane 4 Hydrogenated polydecene 8 Dimethicone 1 Tromethamine 0,19 Exemple 4 : Crème visage Nom INCI UE % (masse) Aqua qsp Uriage Thermal Spring Water 60 Borage seed oil amides aminopropanediol 1 Parfum 0,2 Citric acid 0,028 Phenoxyethanol 0,7 Chlorphenesin 0,3 Glycerin 7 Xanthan gum 0,3 Glyceryl stearate PEG-100 stearate 1,2 Cetearyl isononanoate 5 Propylheptyl caprylate 3 Pentaerythriltyl distearate 2 Cetyl alcohol 0,7 Cetearyl alcohol 2 Glyceryl stearate 1,8 Butyrospermum parkll (shea butter) 5 Tocopheryl acetate 0,5 Dimethicone 1 Cetearyl alcohol cetearyl glucoside2 o-cymen-5-ol 0,1 Butylene glycol 3 Exemple 5 : Lait corporel Nom INCI UE % (masse) Aqua qsp Borage seed oil aminopropanediol amides 5 Butyrospermum parkll (shea butter) 5 Cetearyl isononanoate 5 Isodecyl neopentanoate 4 Butylene glycol 3 Glycerin 3 Hydrogenated polydecene 2,5 Dimethicone 2 Squalane 2 Steareth-2 2 Steareth-21 2 Cetyl alcohol 1 Pentaerythrityl distearate 1 Polyacrylate-13 & polysorbate 20 0,645 Xanthan gum & sorbitan isostearate 0,14 Chlorphenesin & piroctone olamine 0,6 Polyisobutene 0,27 Tocopheryl acetate 0,1 Citric acid 0,105 o-cymen-5-ol 0,1 Butylene glycol 3 Les exemples de compositions illustrés ci-dessus ne sont pas limitatifs et peuvent s'étendre notamment à tous laits, crèmes, lotions, et gels, etc. Les compositions décrites 5 dessus sont préparées selon les règles de l'art en matière, et de la même façon les procédés de préparation crèmes, gels ou lotions selon l'invention sont connus n'ont pas à être détaillés plus avant. Les actifs dans les compositions sont utilisés aux mêmes 10 concentrations que dans les études in vitro précédentes. Leur activité sera équivalente car la plupart des peaux prurigineuses ont une barrière cutanée altérée et la pénétration y est facilitée. Les actifs peuvent donc se retrouver facilement en contact avec les couches cellulaires 15 sous-jacentes, constituées de cellules épidermiques vivantes. Il va de soi que ces exemples de ne sont pas limitatifs et qu'un homme de l'art pourra intégrer d'autres actifs et excipients propres aux domaines cosmétologique et/ou dermatologique. 20 ci- la des etConclusion It is found that at a concentration of 0.005%, omega 6 borage amide significantly stimulates the secretion of resolving lipid mediators, lipoxins and marines (respectively generically referred to as Rv, LX and Mar), natural molecules particularly involved in the resolution. skin inflammation. In addition, omega 6 borage amide significantly inhibits the secretion of pro-inflammatory molecules naturally produced by the body during cutaneous aggression (inflammatory stimulation). Examples of compositions comprising omega 6 amide borage amides (INCI name EU: "Borage seed oil aminopropanediol amides") according to the invention: Example 1: Anti-itching milk - O / W Emulsion INCI Name EU% (mass) Aqua qss Uriage Thermal Spring Water 35 Borage seed oil aminopropanediol amides 0.002 Butyrospermum parkll (shea butter) 5 Cetearyl isononanoate 5 Isodecyl neopentanoate 4 Butylene glycol 3 Glycerin 3 Hydrogenated polydecene 2,5 Dimethicone 2 Squalane 2 Steareth-2 2 Steareth-21 2 Cetyl alcohol 1 Pentaerythrityl distearate 1 Polyacrylate-13 0.6 Brassica campestris sterols 0.5 Chlorphenesin 0.3 Piroctone olamine 0.3 Polyisobutene 0.27 Sodium dextran sulfate 0.2 Citric acid 0.1 o-cymen-5-ol 0.1 Tocopheryl acetate 0.1 Xanthan gum 0.1 Raspberry seed oil / palm oil aminopropanediol esters 0.05 Polysorbate 20 0.045 Sorbitan isostearate 0.04 Asiaticoside 0.02 Phytosphingosine 0.02 Example 2: Cleaning oil INCI name EU% (mass) Aqua qsp Uriage Thermal Spring Water 5 Borage ed oil aminopropanediol amides 0.01 Glycerin 19 Hydrogenated starch hydrolysate 15.4 PEG-7 glyceryl cocoate 2 Sodium cocoyl glutamate 1.8 Sodium laureth sulfate 1.8 Sodium laureth-8 sulfate 1.62 Ceteareth-60 myristyl glycol 1 Polysorbate 20 0 , 97 Coco-glucoside 0.66 Glyceryl oleate 0.66 Sodium chloride 0.646 Citric acid 0.54 Magnesium laureth sulfate 0.45 Sodium oleth sulfate 0.45 Polyquaternum-10 0.364 Magnesium laureth-8 sulfate 0.36 PEG-75 shea butter glycerides 0.25 Magnesium oleth sulfate 0.09 Sodium acetate 0.006 Example 3: Hand cream INCI name EU% (mass) Aqua qsp Uriage Thermal Spring Water 15 Borage seed oil aminopropane diol amides 0.1 Glycerin 3 Phenoxyethanol 0.5 Chlorphenesin 0.2 Acrylates / C10-30 alkyl acrylate crosspolymer 0.17 Glyceryl stearate PEG-100 stearate 3 Cetyl alcohol 2 Cetearyl isononoate 4 Squalane 4 Hydrogenated polydecene 8 Dimethicone 1 Tromethamine 0.19 Example 4: Face cream INCI name EU% (mass) Aqua qsp Uriage Thermal Spring Water 60 Borage Seed Oil amides aminopropanediol 1 Fragrance 0.2 Citric acid 0.028 Phenoxyethanol 0.7 Chlorphenesin 0.3 Glycerin 7 Xanthan gum 0.3 Glyceryl stearate PEG-100 stearate 1,2 Cetearyl isononanoate 5 Propylheptyl caprylate 3 Pentaerythriltyl distearate 2 Cetyl alcohol 0.7 Cetearyl alcohol 2 Glyceryl stearate 1.8 Butyrospermum parkll (shea butter) Tocopheryl acetate 0.5 Dimethicone 1 Cetearyl alcohol cetearyl glucoside 2 o-cymen-5-ol 0.1 Butylene glycol 3 Example 5: Body milk INCI name EU% (mass) Aqua qsp Borage seed oil aminopropanediol amides 5 Butyrospermum parkll (shea butter) 5 Cetearyl isononanoate 5 Isodecyl neopentanoate 4 Butylene glycol 3 Glycerin 3 Hydrogenated polydecene 2,5 Dimethicone 2 Squalane 2 Steareth-2 2 Steareth-21 2 Cetyl alcohol 1 Pentaerythrityl distearate 1 Polyacrylate- 13 & polysorbate 20 0.645 Xanthan gum & sorbitan isostearate 0.14 Chlorphenesin & piroctone olamine 0.6 Polyisobutene 0.27 Tocopheryl acetate 0.1 Citric acid 0.105 o-cymen-5-ol 0.1 Butylene glycol 3 Ex Embodiments of the above illustrated compositions are not limiting and may extend especially to all milks, creams, lotions, and gels, etc. The compositions described above are prepared according to the rules of the art, and in the same way the methods of preparation creams, gels or lotions according to the invention are known do not have to be detailed further. The actives in the compositions are used at the same concentrations as in previous in vitro studies. Their activity will be equivalent because most pruriginous skin has an impaired skin barrier and penetration is facilitated. The actives can thus be easily in contact with the underlying cell layers consisting of living epidermal cells. It goes without saying that these examples are not limiting and one skilled in the art can incorporate other active and excipients specific cosetological and / or dermatological domains. 20 here and
Claims (11)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1303070A FR3015292B1 (en) | 2013-12-23 | 2013-12-23 | COMPOSITION BASED ON OMEGA 6 AMIDE BOURRACHE |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1303070A FR3015292B1 (en) | 2013-12-23 | 2013-12-23 | COMPOSITION BASED ON OMEGA 6 AMIDE BOURRACHE |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR3015292A1 true FR3015292A1 (en) | 2015-06-26 |
| FR3015292B1 FR3015292B1 (en) | 2016-10-07 |
Family
ID=50624641
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR1303070A Active FR3015292B1 (en) | 2013-12-23 | 2013-12-23 | COMPOSITION BASED ON OMEGA 6 AMIDE BOURRACHE |
Country Status (1)
| Country | Link |
|---|---|
| FR (1) | FR3015292B1 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2542873A (en) * | 2015-04-16 | 2017-04-05 | Elc Man Llc | Unit dose packages, compositions, and treatment regimens to deliver pro-resolution pathway stimulators to keratin surfaces |
| FR3047897A1 (en) * | 2016-02-19 | 2017-08-25 | Laboratoires Dermatologiques D'uriage | COSMETIC AND / OR DERMATOLOGICAL COMPOSITION FOR THE TREATMENT OF SKIN LESIONS |
| CN107456447A (en) * | 2017-08-01 | 2017-12-12 | 广东润洁日化有限公司 | A kind of high-efficiency antipruritic preparation for mosquito bites and its preparation |
| US20220339092A1 (en) * | 2016-12-29 | 2022-10-27 | Mary Kay Inc. | Cosmetic compositions and methods |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004256785A (en) * | 2003-02-27 | 2004-09-16 | Yasuhiro Gotoda | Soap containing gammalinolenic acid and fine powder of calcined shell |
| KR20060132158A (en) * | 2005-06-17 | 2006-12-21 | 주식회사 동부한농 | Composition for the prevention and treatment of inflammatory, allergic and atopic diseases containing gamma linolenic acid complex as an active ingredient |
-
2013
- 2013-12-23 FR FR1303070A patent/FR3015292B1/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004256785A (en) * | 2003-02-27 | 2004-09-16 | Yasuhiro Gotoda | Soap containing gammalinolenic acid and fine powder of calcined shell |
| KR20060132158A (en) * | 2005-06-17 | 2006-12-21 | 주식회사 동부한농 | Composition for the prevention and treatment of inflammatory, allergic and atopic diseases containing gamma linolenic acid complex as an active ingredient |
Non-Patent Citations (6)
| Title |
|---|
| "Ses propriétés", 11 October 2010 (2010-10-11), XP002726054, Retrieved from the Internet <URL:http://www.etu.fr/index.php?option=com_content&view=article&id=62&Itemid=68&lang=fr> [retrieved on 20140618] * |
| "Uriage-Pruriced-Relief from itching", 11 August 2012 (2012-08-11), XP002726055, Retrieved from the Internet <URL:http://www.sweetcare.pt/EN/uriage-pruriced-relief-from-itching-p-CM0221UR.aspx> [retrieved on 20140618] * |
| "Xémose lait émollient", 7 December 2013 (2013-12-07), XP002726057, Retrieved from the Internet <URL:http://www.uriage.com/FR/fr/produits/xemose-lait-emollient> [retrieved on 20140618] * |
| DATABASE WPI Week 200752, Derwent World Patents Index; AN 2007-531114, XP002726170 * |
| KANEHARA S ET AL: "Clinical effects of gamma-linolenic acid coated undershirts on children with atopic dermatitis", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 119, no. 1, July 2002 (2002-07-01), & 63RD ANNUAL MEETING OF THE SOCIETY FOR INVESTIGATIVE DERMATOLOGY; LOS ANGELES, CALIFORNIA, USA; MAY 15-18, 2002, pages 241, XP002726171, ISSN: 0022-202X * |
| ZIBOH VINCENT A ET AL: "Metabolism of polyunsaturated fatty acids by skin epidermal enzymes: Generation of antiinflammatory and antiproliferative metabolites", AMERICAN JOURNAL OF CLINICAL NUTRITION, vol. 71, no. 1 Suppl., January 2000 (2000-01-01), pages 361S - 366S, XP002726172, ISSN: 0002-9165 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2542873A (en) * | 2015-04-16 | 2017-04-05 | Elc Man Llc | Unit dose packages, compositions, and treatment regimens to deliver pro-resolution pathway stimulators to keratin surfaces |
| FR3047897A1 (en) * | 2016-02-19 | 2017-08-25 | Laboratoires Dermatologiques D'uriage | COSMETIC AND / OR DERMATOLOGICAL COMPOSITION FOR THE TREATMENT OF SKIN LESIONS |
| US20220339092A1 (en) * | 2016-12-29 | 2022-10-27 | Mary Kay Inc. | Cosmetic compositions and methods |
| US11826456B2 (en) * | 2016-12-29 | 2023-11-28 | Mary Kay Inc. | Cosmetic compositions and methods |
| CN107456447A (en) * | 2017-08-01 | 2017-12-12 | 广东润洁日化有限公司 | A kind of high-efficiency antipruritic preparation for mosquito bites and its preparation |
| CN107456447B (en) * | 2017-08-01 | 2019-11-29 | 广东润洁日化有限公司 | A kind of high-efficiency antipruritic preparation for mosquito bites and its preparation |
Also Published As
| Publication number | Publication date |
|---|---|
| FR3015292B1 (en) | 2016-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1438015B1 (en) | Cosmetic and dermopharmaceutical compositions for skin prone to acne | |
| FR2778562A1 (en) | Compositions containing sea water and basic amino acid inhibit mastocyte activation and basophile degranulation, useful as anti-allergics and anti-inflammatory agents for the skin, eyes, bronchi and nose | |
| CA2309304C (en) | Fatty acid uninterrupted by a methylene as anti-inflammatory agents in superficial tissues of mammals | |
| EP3393488B1 (en) | Composition comprising an ambora extract and a green tea extract for the treatment of psoriasis, atopic dermatitis, chronic urticaria, antihistamine-resistant pruritus and senile pruritus | |
| FR3015292A1 (en) | COMPOSITION BASED ON OMEGA 6 AMIDE BOURRACHE | |
| FR3061434A1 (en) | COSMETIC COMPOSITION COMPRISING AN ASSOCIATION OF PONGAMIA OIL AND PENTYLENE GLYCOL 4-T-BUTYLCYCLOHEXANOL FOR CONTROLLING ROSACEA | |
| JP2006508171A (en) | Topical compositions containing natural ingredients and methods of use | |
| FR3015291A1 (en) | ANTIPRURIGINOUS COMPOSITION | |
| EP2114387B1 (en) | Use of compositions containing at least one lignane and/or neolignane for modulating testosterone levels | |
| WO2006021660A1 (en) | Use of at least one conjugated triene-containing fatty acid for preparing a medicine for treating inflammation | |
| CA2443939A1 (en) | Dermatological composition comprising nicotinic acid or an amide, and a sphingoid base | |
| EP2104496A2 (en) | Use of nepafenac or derivatives thereof for treating dermatological disorders linked with a keratinisation disorder that may include an inflammatory immuno-allergic component | |
| EP1429719B1 (en) | Anti-inflammatory dermocosmetologic composition in particular for treating acne and seborrheic dermatitis | |
| FR2829937A1 (en) | Dermatological or cosmetic composition for treating inflammatory disorders, especially acne or seborrheic dermatitis, containing synergistic combination of zinc or stearyl glycyrrhetinate and lactamide | |
| KR101015909B1 (en) | Cosmetic composition for external skin containing chia seed oil | |
| US20110306577A1 (en) | Topical skin cream comprising phosphatidylcholine dha and l-tyrosine | |
| EP0884948A1 (en) | Antiseptic compositions containing chlorobutanol and chlorhexidine | |
| FR3098394A1 (en) | Composition comprising at least one oxazoline for inhibiting the growth of yeast of the genus Malassezia involved in particular in cradle cap | |
| FR2928837A1 (en) | USE OF AN EXTRACT OF OLIVE OIL FOR THE CONTROL OF SKIN AGING | |
| WO2008062135A1 (en) | Use of adapalene for modulating the expression of il-1ra | |
| FR3065373A1 (en) | COMPOSITION COMPRISING COGNASSIER EXTRACT FOR THE TREATMENT OF PRURIT AND ATOPIC DERMATITIS | |
| FR3065372A1 (en) | COMPOSITION COMPRISING CARBOXY METHYL NARINGENINE CHALCONE FOR THE TREATMENT OF PRURIT AND ATOPIC DERMATITIS | |
| FR2899794A1 (en) | HAIR COSMETIC COMPOSITION | |
| FR2885301A1 (en) | Cosmetic or dermatological composition, useful to reduce and/or control skin redness, comprises active ingredients of polyphenols of vegetable extracts of green tea and/or soya in association with vegetable extracts of Ginkgo biloba leaves | |
| FR2871381A1 (en) | Topical cosmetic/dermatological composition, useful e.g. to fight against signs of cutaneous ageing, comprises an marsh mallow extract (Althea officinalis) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PLFP | Fee payment |
Year of fee payment: 3 |
|
| PLFP | Fee payment |
Year of fee payment: 4 |
|
| PLFP | Fee payment |
Year of fee payment: 5 |
|
| PLFP | Fee payment |
Year of fee payment: 7 |
|
| PLFP | Fee payment |
Year of fee payment: 8 |
|
| PLFP | Fee payment |
Year of fee payment: 9 |
|
| PLFP | Fee payment |
Year of fee payment: 10 |
|
| PLFP | Fee payment |
Year of fee payment: 11 |
|
| PLFP | Fee payment |
Year of fee payment: 12 |